This reduction in PSA expression highlights silibinin’s potential role in disrupting AR signaling pathways, making it a viable therapeutic agent for managing prostate cancer, including castration-resistant prostate cancer (CRPC) [218]. This evidence concerns the gene KLK3 and prostate carcinoma.